PL BioScience GmbH

We at PL BioScience are experts in cell culture supplements derived from human Platelets. Our mission is to enhance the advances in cellular research and therapy with one forward-looking Technology: ELAREM™. The ELAREM™ Platform unites tailored cell culture supplements based on Human Platelet Lysate. The human origin combined with a rich growth factor content not only supports cell growth, but also enables various applications: The products cover all needs of cell expansion in academic research, pre-clinical research and cellular therapy. This ensures seamless transitions in regenerative medicine – from lab to patients in need. Our story goes back to 2015 and the idea to deliver animal component-free cell culture supplements. Today, we have changed the possibilities of cell expansion: Researchers switch from Fetal Bovine Serum to our animal suffering-free products. Stem Cell Therapy benefits the regeneration potential of our platelet-derived products. And we keep moving forward. Let's create the future of cell expansion together and join us on our mission.

https://www.pl-bioscience.com

11-50 employees

Growth Trajectory

PL BioScience is positioned for growth through continued innovation in animal-free cell culture solutions, expansion into clinical applications with GMP-grade products, and strategic partnerships to broaden market reach. Development of advanced 3D cell culture technologies and bioactive bioinks for bioprinting also presents significant growth opportunities. Securing Series A financing is allowing them to expand the commericialization of innovative therapies.

Technical Challenges

Ensuring batch-to-batch consistency in HPL production.

Optimizing HPL modifications such as fibrinogen depletion and virus inactivation.

Integrating HPL products into diverse cell culture workflows.

Complying with regulatory requirements for GMP-grade products.

Avoiding clotting issues in non-fibrinogen-depleted HPL products.

Tech Stack

ELAREM™ TechnologyHuman Platelet Lysate productionFibrinogen depletionVirus inactivationGamma irradiationCRM systemnewsletter providerMailchimpGoogle Tag ManagerGoogle Double ClickYouTubeGoogle AdsenseGoogle AnalyticsGithubhellotrustCloudflare

Team Size

Key Risks

Dependence on consistent and standardized platelet concentrate production.

Challenges in shifting the market away from established FBS usage.

Maintaining compliance with evolving regulations for blood-derived products and GMP-grade manufacturing.

Competition from other cell culture supplement providers, including those offering synthetic alternatives.

Data privacy risks associated with GDPR compliance and international data transfers.

Opportunities

Further develop and commercialize innovative therapies in regenerative medicine, leveraging existing technology.

Expand market reach by offering US and EU origin products to cater to different regulatory environments.

Capitalize on the increasing demand for animal-free and ethically acceptable cell culture solutions.

Strengthen partnerships with research institutions and clinical facilities to drive adoption of HPL products.

Innovate in 3D bioprinting and tissue engineering applications using HPL-based bioinks.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes